Navigation Links
Global Coronary Stents Industry
Date:12/8/2011

NEW YORK, Dec. 8, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Coronary Stents Industry

http://www.reportlinker.com/p098248/Global-Coronary-Stents-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Cardiovas

This report analyzes the worldwide markets for Coronary Stents in US$ Million and Thousand Units by the following Product Segments: Bare Metal Stents, and Drug Eluting Stents. The report provides separate comprehensive analytics for the US, Japan, Europe, Asia Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. A six-year historic analysis is also provided for these markets.The report profiles 53 companies including many key and niche players such as Angiotech Pharmaceuticals, Abbott Vascular, Biosensors International, Boston Scientific Corp., Cordis Corporation, Medtronic, Inc., Medtronic Cardiovascular, Inc., OrbusNeich, and Terumo Europe N.V. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Data Interpretation & Reporting Level 3

Quantitative Techniques & Analytics 3

Product Definitions and Scope of Study 3

Bare Metal Stents 3

Drug Eluting Stents 4

2. GLOBAL MARKET OVERVIEW 5

Growth Revives as Drug Eluting Stents Bounce Back 5

What's Next on Cards in Coronary Stent Market? 5

Market Snapshots 6

Current and Future Analysis 7

Drug Eluting Stents Steal the Show 7

Star Player J&J to Quit DES Business in an Expensive Market

Withdrawal 8

3. MARKET TRENDS AND ISSUES 9

Drug Eluting Stent System - Safety Concerns 9

Declining Prices - A Major Concern 9

Restenosis - the Real Growth Driver 9

Small Vessels - A Major Cause of Restenosis 10

Aging Population Propels Coronary Stent Market 10

Next Generation Stents - A Boon for Treating Coronary Diseases 10

Direct Stenting Systems Spur Growth 11

Drug Choice Impacts Market Entry 11

Threats to Coronary Stents - Alternative Therapies/Devices 11

Cell Transplantation - A Major Threat to Coronary Stents 11

Coronary Stents Market Challenged by Drug Therapy 12

4. COMPETITIVE ANALYSIS 13

Coronary Stents - Leading Players 13

Table 1: Leading Players in the Global Coronary Stents Market

(2010 & 2012) - Percentage Breakdown of Market Share by

Company - Boston Scientific, Abbott (Guidant), Johnson &

Johnson, Medtronic, and Others (includes corresponding

Graph/Chart) 13

Bare Metal Stents - Leading Players 14

Table 2: Leading Players in the Global Bare Metal Stents

Market (2010) - Percentage Breakdown of Share for Abbott,

Johnson & Johnson, Boston Scientific, Medtronic, and Others

(includes corresponding Graph/Chart) 14

Drug-Eluting Stents - Leading Players 14

Table 3: Global Drug Eluting Stents Market (2010): Percentage

Breakdown of Share by Company - Boston Scientific, Abbott

Labs, Johnson and Johnson, Medtronic, Others (includes

corresponding Graph/Chart) 14

Major DES Types in the Market and Leading Manufacturers 14

Comparative Analysis of the Leading Players 15

5. CORONARY DISEASE - A PERSPECTIVE 16

Factors Responsible for Coronary Diseases 16

Controllable Risk Factors 16

High Blood Cholesterol 16

Sedentary Life Style and Habits 16

Smoking Habits 17

High Blood Pressure 17

Uncontrollable Risk Factors 17

Age 17

Heredity 17

Gender 17

Causative Risk Factors 17

Stress and Anger 18

Obesity 18

Diabetes 18

Symptoms of Coronary Artery Disease 18

Diagnosis 18

Treatment 19

Drug Supported Treatments 19

Invasive Treatments 19

Bypass Surgery 19

Percutaneous Transluminal Coronary Angioplasty (Balloon

Angioplasty) 19

Natural Therapy 20

Coronary Angioplasty Suitable for Acute Myocardial Infarction 20

Advancements in Coronary Disease Treatment Modalities 20

University of Virginia's Microbe Solution for Post Surgical

Complications 20

Radiation for Re-clogged Arteries Show Promise 21

Radioactive Coronary Stents Promise Bright Future 21

6. CORONARY STENTS - PRODUCT OVERVIEW 22

Introduction 22

Evolution of Coronary Stents 22

Applications of Coronary Stents 22

Stent Deployment 23

Key Stent Delivery Platforms by Select Company 24

Coronary Stent Designs 24

Key Factors Determining Coronary Stent Performance 24

Delivery Convenience 24

Efficient Scaffolding 24

Radiopacity (Visibility) 25

Optimum Flexibility 25

Shape Conformability 25

Material for Coronary Stent 25

Risk Associated with Stenting 25

Improper Stent Implantation Likely Cause for In-Stent Restenosis 26

Precautions 27

Direct Coronary Stenting - Creating an Enliven 27

Limitations 27

Regulatory Approvals Wooing Stent Market 28

A Peek into Regulatory Approvals for Coronary Stents 28

7. PRODUCT SEGMENTS 30

Bare Metal Stents 30

Major Bare Metal Stents by Company 30

Drug-Eluting Stents 30

DE Stents Overshadow Intravascular Brachytherapy Interventions 31

Major Drug-Eluting Stents by Company 31

Drugs for Coating DESs 31

Cytotoxic or Cytostatic Drug - the Debate Continues 32

Dosing and Deliverability Crucial for DES 32

Polymer Coatings for Effective Dosing and Deliverability 32

Drugs Used for DES by Major Competitors in the Stent Market 32

Leading Coronary Stent Brands 33

Cypher 33

Structure and Delivery Mechanism 33

Taxus 34

Structure and Delivery Mechanism 34

8. RESEARCH AND DEVELOPMENT 35

Extensive R&D Underway in Global Drug-Eluting Stents Market 35

At the Labs 35

Other Products Under Trials - A Recent Past Perspective 35

OMT Developing R-stent 35

Reva Developing Stainless Steel Bare-Metal Stent 35

D&P Corp Developing Bovine Pericardium- Covered Stent 36

Advanced Bio Synthesizing Porous Drug-Eluting Stents 36

Lombard Medical Developing PEP Coatings 36

Shiga Develops Biodegradable Drug-Eluting Stent 36

9. PRODUCT INNOVATIONS/INTRODUCTIONS 37

Boston Scientific Launches ION™ Platinum Chromium Stent System 37

Terumo Introduces Nobori Drug-Eluting Coronary Stent 37

Boston Scientific Unveils TAXUS® Element™ and PROMUS® Element™

Stent Systems 37

Covidien Introduces EverFlex+™ Self-Expanding Peripheral Stent

System 38

Boston Scientific Launches Taxus Element Stent System in

European Union 38

Cordis Introduces PRESILLION™ PLUS Stent System in Europe 38

Medtronic Launches Resolute Integrity Stent System 38

InspireMD Unveils MGuard Prime 39

Boston Scientific Introduces Taxus Eluting Stent System 39

Boston Scientific Unveils TAXUS Liberte Paclitaxel Eluting

Stent System in Japan 39

Alvimedica Launches Coracto Drug-Eluting Stent in Europe 39

Abbott Labs to Launch XIENCE V in China 40

Medtronic Launches Driver Sprint RX Coronary STENT System 40

Existent Introduces Premier Coronary Stent System 40

Medtronic to Unveil Balloon Catheter Systems and Coronary Stents 40

NanoInterventions Launches Mouse Stent Model 40

InspireMD - MGuard™ Coronary Stent Launched in Italy 41

CeloNova BioSciences Launches CATANIA™ Coronary Stent with

NanoThin Polyzene®-F 41

Angiotech Launches Cook Medical's Drug Eluting Zilver® PTX™

Stent in New Zealand 41

10. RECENT INDUSTRY ACTIVITY 42

Boston Scientific Receives FDA Approval for Novel Paclitaxel-

Eluting Coronary Stent 42

Boston Scientific Receives Approval for Distribution of

PROMUS® Everolimus-Eluting Stent 42

Cordis Discontinues Production of NEVO™ Sirolimus- Eluting

Coronary Stents 42

Boston Scientific Receives FDA Approval for ION Stent 43

Abbott Obtains FDA Approval to Extend RX ACCULINK® Carotid

Stent System Application 43

Boston Scientific Receives CE Mark Approval for OMEGA™

Platinum Chromium Stent System 43

Stentys Launches Stents across Additional Countries in Europe 44

Opto Circuits Acquires N.S. Remedies 44

Biosensors International Group Takes Over Assets of Devax 44

Cordis Signs Distribution Agreement with Ostial Solutions 44

Medtronic Obtains FDA Approval for Integrity Coronary Stent

System 44

Boston Scientific Receives Approval from Japanese MHLW for

PROMUS® Coronary Stent 45

InspireMD Selects Kirloskar Technologies for Distributing

Coronary Stent Systems 45

Boston Scientific Expands PROMUS® Everolimus-Eluting Coronary

Stent System 45

Boston Scientific Receives TGS Approval from Australia 46

Svelte Medical Systems Commences Clinical Trial of SOAW

Delivery System 46

Abbott Receives Japan's MHLW Approval for Xience V 46

Opto Circuits Receives Mark Approval from Communite European 46

Abbott Receives Health Canada Approval for XIENCE V® Stent System 46

Medtronic Secures Japan's MHLW Approval for Endeavor® Drug

Eluting Stent 47

Boston Scientific Takes Over Labcoat 47

Micell and Maxcor Sign Strategic Agreement 47

Cordis Receives FDA Approval for Variant of Cypher Sirolimus-

Eluting Coronary Stent 47

Boston Scientific Obtains CE Mark Approval for Promus Element

Everolimus-Eluting Coronary Stent System 47

Cypher Select® Plus Sirolimus-eluting Coronary Stent Gains CE

Mark for Treatment in Diabetic Patients 48

Atrium Medical Obtains CE Mark for Cinatra™ 48

Medtronic Secures CE Mark Approval for Endeavor Drug-Eluting

Stent for Use in Treatment of ACS 48

CorNova® Obtains CE mark approval for Valecor Platinum

Coronary Stent System 48

Cook Medical Receives CE Mark Approval and Launches Zilver®

PTX® Drug-Eluting Peripheral Stent 49

Disa Receives CE Approval for Coronary Stent 49

Datascope Acquires Peripheral Stent Business of Sorin Group 49

Boston Scientific Receives FDA approval for TAXUS® Liberte®

Drug-Eluting STENT 49

Abbott Labs Receives FDA Approval for Xience V 49

Bard to Purchase Assets of LifeStent Product Portfolio 50

Medtronic Receives the US FDA Approval to Use Endeavor® Stent 50

Medtronic Inc. Receives Approval for its Drug-Eluting Stent,

"Endeavor" In Canada 50

Boston Scientific to Market TAXUS® Liberte® Stent System in

Canada 50

Abbott Applies for Approval of XIENCE™ V in Japan 51

Medinol Achieves CE Mark Approval for Presillion™ Cobalt

Chromium Coronary Stent System 51

Iberhospitex Receives Spanish Approval to Sell Palau Pharma's

"Active" Coronary Stent 51

Clearstream's Intrepide Drug Eluting Stent of Clearstream

Receives CE mark approval 51

Terumo Introduces Its Drug-Eluting Stent in Germany and Marks

Its European Entry 52

Tryton Medical's Side-Branch Stent Achieves CE Mark Approval 52

CV Therapeutics Offers its Stent Coating Technology to

Medlogics Device Corporation 52

Abbott's 2.25mm-Sized XIENCE™ V Drug Eluting Stent receives CE

Mark of Approval 52

Biosensors Receives CE Mark Approval for BioMatrix® Stent System 53

Nfocus Neuromedical's CardioVasc™ Stent-Graft and Delivery

System Receives CE Mark Approval 53

11. FOCUS ON SELECT GLOBAL PLAYERS 54

Angiotech Pharmaceuticals (Canada) 54

Abbott Vascular (USA) 54

Biosensors International (USA) 54

Boston Scientific Corp. (USA) 55

Cordis Corporation (JNJ) - (USA) 55

Medtronic, Inc. (USA) 56

Medtronic Cardiovascular, Inc. (USA) 56

OrbusNeich (Hong Kong) 56

Terumo Europe N.V. (Belgium) 56

12. GLOBAL MARKET PERSPECTIVE 57

Table 4: World Recent Past, Current & Future Analysis for

Coronary Stents By Geographic Region - US, Japan, Europe,

Asia-Pacific (Excluding Japan) and Rest of World Markets

Independently Analyzed with Annual Sales in US$ Million for

years 2009 through 2017 (includes corresponding Graph/Chart) 57

Table 5: World Recent Past, Current & Future Analysis for

Coronary Stents by Geographic Region - US, Japan, Europe,

Asia-Pacific (Excluding Japan) and Rest of World Markets

Independently Analyzed with Annual Sales in Thousand Units for

years 2009 through 2017 (includes corresponding Graph/Chart) 58

Table 6: World Historic Review for Coronary Stents by

Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding

Japan) and Rest of World Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2003 through 2008

(includes corresponding Graph/Chart) 59

Table 7: World Historic Review for Coronary Stents by

Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding

Japan) and Rest of World Markets Independently Analyzed with

Annual Sales in Thousand Units for Years 2003 through 2008

(includes corresponding Graph/Chart) 60

Table 8: World 15-Year Perspective for Coronary Stents by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of

World Markets for Years 2003, 2010 & 2017 (includes

corresponding Graph/Chart) 61

Table 9: World 15-Year Perspective for Coronary Stents by

Geographic Region - Percentage Breakdown of Unit Sales for US,

Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of

World Markets for Years 2003, 2010 & 2017 (includes

corresponding Graph/Chart) 62

Table 10: World Recent Past, Current & Future Analysis for

Coronary Stents by Product Segment - Bare Metal Stents and

Drug Eluting Stents Markets Independently Analyzed with Annual

Sales in US$ Million for years 2009 through 2017 (includes

corresponding Graph/Chart) 63

Table 11: World Recent Past, Current & Future Analysis for

Coronary Stents by Product Segment-Bare Metal Stents and Drug

Eluting Stents Markets Independently Analyzed with Annual

Sales in Thousand Units for years 2009 through 2017 (includes

corresponding Graph/Chart) 64

Table 12: World Historic Review for Coronary Stents by Product

Segment-Bare Metal Stents and Drug Eluting Stents Markets

Independently Analyzed with Annual Sales in US$ Million for

Years 2003 through 2008 (includes corresponding Graph/Chart) 65

Table 13: World Historic Review for Coronary Stents by Product

Segment-Bare Metal Stents and Drug Eluting Stents Markets

Independently Analyzed with Annual Sales in Thousand Units for

Years 2003 through 2008 (includes corresponding Graph/Chart) 66

Table 14: World 15-Year Perspective for Coronary Stents by

Product Segment - Percentage Breakdown of Dollar Sales for

Bare Metal Stents and Drug Eluting Stents Markets for Years

2003, 2010 & 2017 (includes corresponding Graph/Chart) 67

Table 15: World 15-Year Perspective for Coronary Stents by

Product Segment - Percentage Breakdown of Unit Sales for Bare

Metal Stents and Drug Eluting Stents Markets for Years 2003,

2010 & 2017 (includes corresponding Graph/Chart) 68

Table 16: World Recent Past, Current & Future Analysis for

Bare Metal Stents by Geographic Region - US, Japan, Europe,

Asia - Pacific (Excluding Japan) and Rest of World Markets

Independently Analyzed with Annual Sales in US$ Million for

years 2009 through 2017 (includes corresponding Graph/Chart) 69

Table 17: World Recent Past, Current & Future Analysis for

Bare Metal Stents by Geographic Region - US, Japan, Europe,

Asia - Pacific (Excluding Japan) and Rest of World Markets

Independently Analyzed with Annual Sales in Thousand Units for

years 2009 through 2017 (includes corresponding Graph/Chart) 70

Table 18: World Historic Review for Bare Metal Stents By

Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding

Japan) and Rest of World Markets Independently Analyzed with

Annual Sale sin US$ Million for Years 2003 through

2008(includes corresponding Graph/Chart) 71

Table 19: World Historic Review for Bare Metal Stents By

Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding

Japan) and Rest of World Markets Independently Analyzed with

Annual Sales in Thousand Units for Years 2003 through 2008

(includes corresponding Graph/Chart) 72

Table 20: World 15-Year Perspective for Bare Metal Stents by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of

World Markets for Years 2003, 2010 & 2017 (includes

corresponding Graph/Chart) 73

Table 21: World 15-Year Perspective for Bare Metal Stents by

Geographic Region - Percentage Breakdown of Unit Sales for US,

Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of

World Markets for Years 2003, 2010 & 2017 (includes

corresponding Graph/Chart) 74

Table 22: World Recent Past, Current & Future Analysis for

Drug Eluting Stents by Geographic Region - US, Japan, Europe,

Asia - Pacific (Excluding Japan), and Rest of World Markets

Independently Analyzed with Annual Sales in US$ Million for

Years 2009 through 2017 (includes corresponding Graph/Chart) 75

Table 23: World Recent Past, Current & Future Analysis for

Drug Eluting Stents by Geographic Region - US, Japan, Europe,

Asia - Pacific (Excluding Japan), and Rest of World Markets

Independently Analyzed with Annual Sales in Thousand Units for

Years 2009 through 2017 (includes corresponding Graph/Chart) 76

Table 24: World Historic Review for Drug Eluting Stents by

Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding

Japan) and Rest of World Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2003 through 2008

(includes corresponding Graph/Chart) 77

Table 25: World Historic Review for Drug Eluting Stents by

Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding

Japan) and Rest of World Markets Independently Analyzed with

Annual Sales in Thousand Units for Years 2003 through 2008

(includes corresponding Graph/Chart) 78

Table 26: World 15-Year Perspective for Drug Eluting Stents by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of

World Markets for Years 2003, 2010 & 2017 (includes

corresponding Graph/Chart) 79

Table 27: World 15-Year Perspective for Drug Eluting Stents by

Geographic Region - Percentage Breakdown of Unit Sales for US,

Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of

World Markets for Years 2003, 2010 & 2017 (includes

corresponding Graph/Chart) 80

13. THE UNITED STATES 81

A.Market Analysis 81

Largest Market Worldwide 81

Coronary Artery Disease - A US Perspective 81

Baby Boomers Boost Coronary Stent Market 81

Revival in the DES Market 81

Reimbursement System 82

National Average Medicare Payment For DRGS 82

Competitive Scenario 82

Leading Players 82

Coronary Stents - Boston Scientific and JNJ Battle for

Dominance 82

Table 28: Leading Players in the US Coronary Stents

Market (2010) - Percentage Breakdown of Share for Boston

Scientific, Abbott and Johnson & Johnson (includes

corresponding Graph/Chart) 83

Drug Eluting Stents - Competition in the Brewing 83

Table 29: Leading Players in the US Drug-Eluting Stents

Market (2010) - Percentage Breakdown of share for Boston

Scientific, Abbott Labs, J&J-Cordis and Medtronic

(includes corresponding Graph/Chart) 83

Regulatory Environment 84

B.Market Analytics 84

Table 30: US Recent Past, Current & Future Analysis for

Coronary Stents by Product Segment - Bare Metal and Drug

Eluting Stent Markets Independently Analyzed with Annual

Sales in US$ Million for years 2009 through 2017 (includes

corresponding Graph/Chart) 84

Table 31: US Recent Past, Current & Future Analysis for

Coronary Stents by Product Segment - Bare Metal and Drug

Eluting Stent Markets Independently Analyzed with Annual

Sales in Thousand Units for years 2009 through 2017

(includes corresponding Graph/Chart) 85

Table 32: US Historic Review for Coronary Stents by Product

Segment - Bare Metal and Drug Eluting Stent Markets

Independently Analyzed with Annual Sales in US$ Million for

years 2003 through 2008 (includes corresponding Graph/Chart) 86

Table 33: US Historic Review for Coronary Stents by Product

Segment - Bare Metal and Drug Eluting Stent Markets

Independently Analyzed with Annual Sales in Thousand Units

for years 2003 through 2008 (includes corresponding

Graph/Chart) 87

Table 34: US 15-Year Perspective for Coronary Stents by

Product Segment - Percentage Breakdown of Dollar Sales for

Bare Metal Stents and Drug Eluting Stents Markets for years

2003, 2010 & 2017 (includes corresponding Graph/Chart) 88

Table 35: US 15-Year Perspective for Coronary Stents by

Product Segment - Percentage Breakdown of Unit Sales for

Bare Metal Stents and Drug Eluting Stents Markets for years

2003, 2010 & 2017 (includes corresponding Graph/Chart) 89

14. JAPAN 90

A.Market Analysis 90

Prospects Weighed down by Regulatory Entanglements 90

Japanese Coronary Stents Command Higher Prices 90

Table 36: Coronary Stent Pricing (2008): Comparative

Analysis of Prices in Japan, US, Europe and Global Average

(includes corresponding Graph/Chart) 90

Competitive Landscape 91

Table 37: Leading Players in the Japanese Coronary Stent

Market ( 2010) - Percentage Breakdown of Share for Johnson &

Johnson, Medtronic, Boston Scientific, and Others

(includes corresponding Graph/Chart) 91

Table 38: Leading Players in the Japanese Bare Metal Stent

Market (2010) - Percentage Breakdown by of Share for

Medtronic, Boston Scientific, JNJ and Others (includes

corresponding Graph/Chart) 92

Table 39: Leading Players in Japanese Drug-Eluting Stent

Market (2010) - Percentage Breakdown of Share for Johnson &

Johnson and Boston Scientific (includes corresponding

Graph/Chart) 92

B.Market Analytics 93

Table 40: Japanese Recent Past, Current & Future Analysis

for Coronary Stents by Product Segment - Bare Metal and Drug

Eluting Stent Markets Independently Analyzed with Annual

Sales in US$ Million for years 2009 through 2017 (includes

corresponding Graph/Chart) 93

Table 41: Japanese Recent Past, Current & Future Analysis

for Coronary Stents by Product Segment - Bare Metal and Drug

Eluting Stent Markets Independently Analyzed with Annual

Sales in Thousand Units for years 2009 through 2017

(includes corresponding Graph/Chart) 94

Table 42: Japanese Historic Review for Coronary Stents by

Product Segment - Bare Metal and Drug Eluting Stent Markets

Independently Analyzed with Annual Sales in US$ Million for

years 2003 through 2008 (includes corresponding Graph/Chart) 95

Table 43: Japanese Historic Review for Coronary Stents by

Product Segment - Bare Metal and Drug Eluting Stent Markets

Independently Analyzed with Annual Sales in Thousand Units

for years 2003 through 2008 (includes corresponding

Graph/Chart) 96

Table 44: Japanese 15-Year Perspective for Coronary Stents

by Product Segment - Percentage Breakdown of Dollar Sales

for Bare Metal Stents and Drug Eluting Stents Markets for

years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 97

Table 45: Japanese 15-Year Perspective for Coronary Stents

by Product Segment - Percentage Breakdown of Unit Sales for

Bare Metal Stents and Drug Eluting Stents Markets for years

2003, 2010 & 2017 (includes corresponding Graph/Chart) 98

15. EUROPE 99

A.Market Analysis 99

Cardiovascular Disease in Europe - A Perspective 99

Growth Bar Too Low 99

Two-Speed Europe 99

Stent Market's Merger Mania 100

Dampeners to Rapid Adoption of DES in Europe 100

Competitive Scenario 101

Table 46: Leading Players in the European Drug- Eluting

Stent Market (2010) - Percentage Breakdown of Share for

Johnson & Johnson, Boston Scientific, Medtronic, and Others

(includes corresponding Graph/Chart) 101

B.Market Analytics 102

Table 47: European Recent Past, Current & Future Analysis

for Coronary Stents by Geographic Region - France, Germany,

Italy, UK, Spain, Russia and Rest of Europe Markets

Independently Analyzed with Annual Sales in US$ Million for

years 2009 through 2017 (includes corresponding Graph/Chart) 102

Table 48: European Recent Past, Current & Future Analysis

for Coronary Stents by Geographic Region - France, Germany,

Italy, UK, Spain, Russia and Rest of Europe Markets

Independently Analyzed with Annual Sales in Thousand Units

for years2009 through 2017 (includes corresponding

Graph/Chart) 103

Table 49: European Historic Review for Coronary Stents by

Geographic Region - France, Germany, Italy, UK, Spain,

Russia and Rest of Europe Markets Independently Analyzed

with Annual Sales in US$ Million for years 2003 through 2008

(includes corresponding Graph/Chart) 104

Table 50: European Historic Review for Coronary Stents by

Geographic Region - France, Germany, Italy, UK, Spain,

Russia and Rest of Europe Markets Independently Analyzed

with Annual Sales in Thousand Units for years 2003 through

2008 (includes corresponding Graph/Chart) 105

Table 51: European 15-Year Perspective for Coronary Stents

by Geographic Region - Percentage Breakdown of Dollar Sales

for France, Germany, Italy, UK, Spain, Russia and Rest of

Europe Markets for Years 2003, 2010 & 2017 (includes

corresponding Graph/Chart) 106

Table 52: European 15-Year Perspective for Coronary Stents

by Geographic Region - Percentage Breakdown of Unit Sales

for France, Germany, Italy, UK, Spain, Russia and Rest of

Europe Markets for Years 2003, 2010 & 2075 (includes

corresponding Graph/Chart) 107

Table 53: European Recent Past, Current & Future Analysis

for Coronary Stents by Product Segment - Bare Metal and Drug

Eluting Stents Markets Independently Analyzed with Annual

sales in US$ Million for years 2009 through 2017 (includes

corresponding Graph/Chart) 108

Table 54: European Recent Past, Current & Future Analysis

for Coronary Stents by Product Segment - Bare Metal and Drug

Eluting Stents Markets Independently Analyzed with Annual

sales in Thousand Units for years 2009 through 2017

(includes corresponding Graph/Chart) 109

Table 55: European Historic Review for Coronary Stents by

Product Segment - Bare Metal and Drug Eluting Stent Markets

Independently Analyzed with Annual Sales in US$ Million for

years 2003 through 2008 (includes corresponding Graph/Chart) 110

Table 56: European Historic Review for Coronary Stents by

Product Segment - Bare Metal and Drug Eluting Stent Markets

Independently Analyzed with Annual Sales in Thousand Units

for years 2003 through 2008 (includes corresponding

Graph/Chart) 111

Table 57: European 15-Year Perspective for Coronary Stents

by Product Segment - Percentage Breakdown of Dollar Sales

for Bare Metal Stents and Drug Eluting Stents Markets for

years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 112

Table 58: European 15-Year Perspective for Coronary Stents

by Product Segment - Percentage Breakdown of Unit Sales for

Bare Metal Stents and Drug Eluting Stents Markets for years

2003, 2010 & 2017 (includes corresponding Graph/Chart) 113

15a. FRANCE 114

Market Analysis 114

Table 59: French Recent Past, Current & Future Analysis for

Coronary Stents by Product Segment - Bare Metal Stent and

Drug Eluting Stent Markets Independently Analyzed with

Annual Sales in US$ Million for years 2009 through 2017

(includes corresponding Graph/Chart) 114

Table 60: French Recent Past, Current & Future Analysis for

Coronary Stents by Product Segment - Bare Metal Stent and

Drug Eluting Stent Markets Independently Analyzed with

Annual Sales in Thousand Units for years 2009 through 2017

(includes corresponding Graph/Chart) 115

Table 61: French Historic Review for Coronary Stents by

Product Segment - Bare Metal and Drug Eluting Stent Markets

Independently Analyzed with Annual Sales in US$ Million for

years 2003 through 2008 (includes corresponding Graph/Chart) 116

Table 62: French Historic Review for Coronary Stents by

Product Segment - Bare Metal and Drug Eluting Stent Markets

Independently Analyzed with Annual Sales in Thousand Units

for years 2003 through 2008 (includes corresponding

Graph/Chart) 117

Table 63: French 15-Year Perspective for Coronary Stents by

Product Segment - Percentage Breakdown of Dollar Sales for

Bare Metal Stents and Drug Eluting Stents Markets for years

2003, 2010 & 2017 (includes corresponding Graph/Chart) 118

Table 64: French 15-Year Perspective for Coronary Stents by

Product Segment - Percentage Breakdown of Unit Sales for

Bare Metal Stents and Drug Eluting Stents Markets for years

2003, 2010 & 2017 (includes corresponding Graph/Chart) 119

15b. GERMANY 120

Market Analysis 120

Table 65: German Recent Past, Current & Future Analysis for

Coronary Stents by Product Segment - Bare Metal Stent and

Drug Eluting Stent Markets Independently Analyzed with

Annual Sales in US$ Million for years 2009 through 2017

(includes corresponding Graph/Chart) 120

Table 66: German Recent Past, Current & Future Analysis for

Coronary Stents by Product Segment - Bare Metal Stent and

Drug Eluting Stent Markets Independently Analyzed with

Annual Sales in Thousand Units for years 2009 through 2017

(includes corresponding Graph/Chart) 121

Table 67: German Historic Review for Coronary Stents by

Product Segment - Bare Metal and Drug Eluting Stent Markets

Independently Analyzed with Annual Sales in US$ Million for

years 2003 through 2008 (includes corresponding Graph/Chart) 122

Table 68: German Historic Review for Coronary Stents by

Product Segment - Bare Metal and Drug Eluting Stent Markets

Independently Analyzed with Annual Sales in Thousand Units

for years 2003 through 2008 (includes corresponding

Graph/Chart) 123

Table 69: German 15-Year Perspective for Coronary Stents by

Product Segment - Percentage Breakdown of Dollar Sales for

Bare Metal Stents and Drug Eluting Stents Markets for years

2003, 2010 & 2017 (includes corresponding Graph/Chart) 124

Table 70: German 15-Year Perspective for Coronary Stents by

Product Segment - Percentage Breakdown of Unit Sales for

Bare Metal Stents and Drug Eluting Stents Markets for years

2003, 2010 & 2017 (includes corresponding Graph/Chart) 125

15c. ITALY 126

Market Analysis 126

Table 71: Italian Recent Past, Current & Future Analysis for

Coronary Stents by Product Segment - Bare Metal Stent and

Drug Eluting Stent Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) 126

Table 72: Italian Recent Past, Current & Future Analysis for

Coronary Stents by Product Segment - Bare Metal Stent and

Drug Eluting Stent Markets Independently Analyzed with

Annual Sales in Thousand Units for years 2009 through 2017

(includes corresponding Graph/Chart) 127

Table 73: Italian Historic Review for Coronary Stents by

Product Segment - Bare Metal and Drug Eluting Stent Markets

Independently Analyzed with Annual Sales in US$ Million for

years 2003 through 2008 (includes corresponding Graph/Chart) 128

Table 74: Italian Historic Review for Coronary Stents by

Product Segment - Bare Metal and Drug Eluting Stent Markets

Independently Analyzed with Annual Sales in Thousand Units

for years 2003 through 2008 (includes corresponding

Graph/Chart) 129

Table 75: Italian 15-Year Perspective for Coronary Stents by

Product Segment - Percentage Breakdown of Dollar Sales for

Bare Metal Stents and Drug Eluting Stents Markets for years

2003, 2010 & 2017 (includes corresponding Graph/Chart) 130

Table 76: Italian 15-Year Perspective for Coronary Stents by

Product Segment - Percentage Breakdown of Unit Sales for

Bare Metal Stents and Drug Eluting Stents Markets for years

2003, 2010 & 2017 (includes corresponding Graph/Chart) 131

15d. THE UNITED KINGDOM 132

Market Analysis 132

Table 77: UK Recent Past, Current & Future Analysis for

Coronary Stents by Product Segment - Bare Metal Stent and

Drug Eluting Stent Markets Independently Analyzed with

Annual Sales in US$ Million for years 2009 through 2017

(includes corresponding Graph/Chart) 132

Table 78: UK Recent Past, Current & Future Analysis for

Coronary Stents by Product Segment - Bare Metal Stent and

Drug Eluting Stent Markets Independently Analyzed with

Annual Sales in Thousand Units for years 2009 through 2017

(includes corresponding Graph/Chart) 133

Table 79: UK Historic Review for Coronary Stents by Product

Segment - Bare Metal and Drug Eluting Stent Markets

Independently Analyzed with Annual Sales in US$ Million for

years 2003 through 2008 (includes corresponding Graph/Chart) 134

Table 80: UK Historic Review for Coronary Stents by Product

Segment - Bare Metal and Drug Eluting Stent Markets

Independently Analyzed with Annual Sales in Thousand Units

for years 2003 through 2008 (includes corresponding

Graph/Chart) 135

Table 81: UK 15-Year Perspective for Coronary Stents by

Product Segment - Percentage Breakdown of Dollar Sales for

Bare Metal Stents and Drug Eluting Stents Markets for years

2003, 2010 & 2017 (includes corresponding Graph/Chart) 136

Table 82: UK 15-Year Perspective for Coronary Stents by

Product Segment - Percentage Breakdown of Unit Sales for

Bare Metal Stents and Drug Eluting Stents Markets for years

2003, 2010 & 2017 (includes corresponding Graph/Chart) 137

15e. SPAIN 138

Market Analysis 138

Table 83: Spanish Recent Past, Current & Future Analysis for

Coronary Stents by Product Segment - Bare Metal Stent and

Drug Eluting Stent Markets Independently Analyzed with

Annual Sales in US$ Million for years 2009 through 2017

(includes corresponding Graph/Chart) 138

Table 84: Spanish Recent Past, Current & Future Analysis for

Coronary Stents by Product Segment - Bare Metal Stent and

Drug Eluting Stent Markets Independently Analyzed with

Annual Sales in Thousand Units for years 2009 through 2017

(includes corresponding Graph/Chart) 139

Table 85: Spanish Historic Review for Coronary Stents by

Product Segment - Bare Metal and Drug Eluting Stent Markets

Independently Analyzed with Annual Sales in US$ Million for

years 2003 through 2008 (includes corresponding Graph/Chart) 140

Table 86: Spanish Historic Review for Coronary Stents by

Product Segment - Bare Metal and Drug Eluting Stent Markets

Independently Analyzed with Annual Sales in Thousand Units

for years 2003 through 2008 (includes corresponding

Graph/Chart) 141

Table 87: Spanish 15-Year Perspective for Coronary Stents by

Product Segment - Percentage Breakdown of Dollar Sales for

Bare Metal Stents and Drug Eluting Stents Markets for years

2003, 2010 & 2017 (includes corresponding Graph/Chart) 142

Table 88: Spanish 15-Year Perspective for Coronary Stents by

Product Segment - Percentage Breakdown of Unit Sales for

Bare Metal Stents and Drug Eluting Stents Markets for years

2003, 2010 & 2017 (includes corresponding Graph/Chart) 143

15f. RUSSIA 144

Market Analysis 144

Table 89: Russian Recent Past, Current & Future Analysis for

Coronary Stents by Product Segment - Bare Metal Stent and

Drug Eluting Stent Markets Independently Analyzed with

Annual Sales in US$ Million for years 2009 through 2017

(includes corresponding Graph/Chart) 144

Table 90: Russian Recent Past, Current & Future Analysis for

Coronary Stents by Product Segment - Bare Metal Stent and

Drug Eluting Stent Markets Independently Analyzed with

Annual Sales in Thousand Units for years 2009 through 2017

(includes corresponding Graph/Chart) 145

Table 91: Russian Historic Review for Coronary Stents by

Product Segment - Bare Metal and Drug Eluting Stent Markets

Independently Analyzed with Annual Sales in US$ Million for

years 2003 through 2008 (includes corresponding Graph/Chart) 146

Table 92: Russian Historic Review for Coronary Stents by

Product Segment - Bare Metal and Drug Eluting Stent Markets

Independently Analyzed with Annual Sales in Thousand Units

for years 2003 through 2008 (includes corresponding

Graph/Chart) 147

Table 93: Russian 15-Year Perspective for Coronary Stents by

Product Segment - Percentage Breakdown of Dollar Sales for

Bare Metal Stents and Drug Eluting Stents Markets for years

2003, 2010 & 2017 (includes corresponding Graph/Chart) 148

Table 94: Russian 15-Year Perspective for Coronary Stents by

Product Segment - Percentage Breakdown of Unit Sales for

Bare Metal Stents and Drug Eluting Stents Markets for years

2003, 2010 & 2017 (includes corresponding Graph/Chart) 149

15g. REST OF EUROPE 150

Market Analysis 150

Table 95: Rest of Europe Recent Past, Current & Future

Analysis for Coronary Stents by Product Segment - Bare Metal

Stent and Drug Eluting Stent Markets Independently Analyzed

with Annual Sales in US$ Million for years 2009 through 2017

(includes corresponding Graph/Chart) 150

Table 96: Rest of Europe Recent Past, Current & Future

Analysis for Coronary Stents by Product Segment - Bare Metal

Stent and Drug Eluting Stent Markets Independently Analyzed

with Annual Sales in Thousand Units for years 2009 through

2017 (includes corresponding Graph/Chart) 151

Table 97: Rest of Europe Historic Review for Coronary Stents

by Product Segment - Bare Metal and Drug Eluting Stent

Markets Independently Analyzed with Annual Sales in US$

Million for years 2003 through 2008 (includes corresponding

Graph/Chart) 152

Table 98: Rest of Europe Historic Review for Coronary Stents

by Product Segment - Bare Metal and Drug Eluting Stent

Markets Independently Analyzed with Annual Sales in Thousand

Units for years 2003 through 2008 (includes corresponding

Graph/Chart) 153

Table 99: Rest of Europe 15-Year Perspective for Coronary

Stents by Product Segment - Percentage Breakdown of Dollar

Sales for Bare Metal Stents and Drug Eluting Stents Markets

for years 2003, 2010 & 2017 (includes corresponding

Graph/Chart) 154

Table 100: Rest of Europe 15-Year Perspective for Coronary

Stents by Product Segment - Percentage Breakdown of Unit

Sales for Bare Metal Stents and Drug Eluting Stents Markets

for years 2003, 2010 & 2017 (includes corresponding

Graph/Chart) 155

16. ASIA-PACIFIC 156

A.Market Analysis 156

China - Healthcare Reforms to Propel DES Market 156

Table 101: Coronary Stent Market in China (2010):

Percentage Breakdown of Market Share by Company- Shanghai

Microport, Beijing Lepu, JW Medical, J&J Cordis, Medtronic

and Others (includes corresponding Graph/Chart) 156

Coronary Stent Market in a Bubble Zone Now 157

Regional Players and their DES Development Efforts 157

Cost Focus Helps Stent Makers Win the Market Stunt 157

B.Market Analytics 158

Table 102: Asia-Pacific Recent Past, Current & Future

Analysis for Coronary Stents by Product Segment - Bare Metal

Stent and Drug Eluting Stent Markets Independently Analyzed

with Annual Sales in US$ Million for years 2009 through 2017

(includes corresponding Graph/Chart) 158

Table 103: Asia-Pacific Recent Past, Current & Future

Analysis for Coronary Stents by Product Segment - Bare Metal

Stent and Drug Eluting Stent Markets Independently Analyzed

with Annual Sales in Thousand Units for years 2009 through

2017 (includes corresponding Graph/Chart) 159

Table 104: Asia-Pacific Historic Review for Coronary Stents

by Product Segment - Bare Metal and Drug Eluting Stent

Markets Independently Analyzed with Annual Sales in US$

Million for years 2003 through 2008(includes corresponding

Graph/Chart) 160

Table 105: Asia-Pacific Historic Review for Coronary Stents

by Product Segment - Bare Metal and Drug Eluting Stent

Markets Independently Analyzed with Annual Sales in Thousand

Units for years 2003 through 2008(includes corresponding

Graph/Chart) 161

Table 106: Asia-Pacific 15-Year Perspective for Coronary

Stents by Product Segment - Percentage Breakdown of Dollar

Sales for Bare Metal Stents and Drug Eluting Stents Markets

for years 2003, 2010 & 2017 (includes corresponding

Graph/Chart) 162

Table 107: Asia-Pacific 15-Year Perspective for Coronary

Stents by Product Segment - Percentage Breakdown of Unit

Sales for Bare Metal Stents and Drug Eluting Stents Markets

for years 2003, 2010 & 2017 (includes corresponding

Graph/Chart) 163

17. REST OF WORLD 164

A.Market Analysis 164

Brazil - Low Penetration of DES 164

South Africa - Leading Players 164

Table 108: Leading Players in South African Coronary Stent

Market (2010) - Percentage Breakdown by Unit Sales for

Johnson & Johnson, Boston Scientific, Guidant, Abbott and

Others (includes corresponding Graph/Chart) 164

B.Market Analytics 165

Table 109: Rest of World Recent Past, Current & Future

Analysis for Coronary Stents by Product Segment - Bare Metal

Stent and Drug Eluting Stent Markets Independently Analyzed

with Annual Sales in US$ Million for years 2009 through 2017

(includes corresponding Graph/Chart) 165

Table 110: Rest of World Recent Past, Current & Future

Analysis for Coronary Stents by Product Segment - Bare Metal

Stent and Drug Eluting Stent Markets Independently Analyzed

with Annual Sales in Thousand Units for years 2009 through

2017 (includes corresponding Graph/Chart) 166

Table 111: Rest of World Historic Review for Coronary Stents

by Product Segment - Bare Metal and Drug Eluting Stent

Markets Independently Analyzed with Annual Sales in US$

Million for years 2003 through 2008 (includes corresponding

Graph/Chart) 167

Table 112: Rest of World Historic Review for Coronary Stents

by Product Segment - Bare Metal and Drug Eluting Stent

Markets Independently Analyzed with Annual Sales in Thousand

Units for years 2003 through 2008 (includes corresponding

Graph/Chart) 168

Table 113: Rest of World 15-Year Perspective for Coronary

Stents by Product Segment - Percentage Breakdown of Dollar

Sales for Bare Metal Stents and Drug Eluting Stents Markets

for years 2003, 2010 & 2017 (includes corresponding

Graph/Chart) 169

Table 114: Rest of World 15-Year Perspective for Coronary

Stents by Product Segment - Percentage Breakdown of Unit

Sales for Bare Metal Stents and Drug Eluting Stents Markets

for years 2003, 2010 & 2017 (includes corresponding

Graph/Chart) 170

COMPETITIVE LANDSCAPE

Total Companies Profiled: 53 (including Divisions/Subsidiaries - 62)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 34

Canada 1

Japan 3

Europe 15

France 1

Germany 5

The United Kingdom 1

Italy 1

Spain 1

Rest of Europe 6

Asia-Pacific (Excluding Japan) 5

Middle-East 2

Africa 2

------------------------------------------

To order this report:

Cardiovascular Devices Industry: Global Coronary Stents Industry

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
2. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
3. Directors Forum: PEPFAR and the Global AIDS Response
4. Alfacell Corporation to Present at UBS Global Life Sciences Conference
5. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
6. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
7. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
8. Hillary Clinton Pledges Bold Approach to Stopping HIV/AIDS & Global Poverty
9. IBA and Elekta Initiate Global Particle Therapy Program at ASTRO
10. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
11. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... 25, 2016 Digital Health Dialog, LLC ... by the US Patent and Trademark Office of ... proprietary processes for electronic opt-­in and processing of ... programs, HIPAA compliance and otherwise. Logo - ... "Our technology allows for individuals to ...
(Date:5/24/2016)... 24, 2016 Niederländische Chirurgen ... die es Ärzten erlaubt, ihre Expertise weltweit zu ... kombiniert Live Streaming mit einer Instant-Messaging-Funktion und der ... Mediziner in Europa, Afrika, Asien und den ... die Plattform registriert. Information und Weiterbildung   ...
(Date:5/24/2016)... May 24, 2016  Diana Russell suffers from a ... from the inside out.  This disease has put her ... her children and grandchildren to leave her home.  Because ... family cannot haul the wheelchair.  So if there is ... and Diana is left to wait for the bus. ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... ... MadgeTech will be showcasing its line of data logging products , ... MadgeTech headquarters. With products sold in more than 100 countries around the world, MadgeTech ... , In 2012, NASA strategically set up 17 RHTemp101A MadgeTech data loggers around ...
(Date:5/26/2016)... ... May 26, 2016 , ... An April Gallup survey found rising health care ... of Sun Health Senior Living (SHSL) may not share those same worries ... prescription copays for the year, while holding the line on increasing their contributions, including ...
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership of ... today announced the organization has earned its ISO 13485 certification, indicating the company’s ... with all rules and policies associated with ISO quality standard 13485. , ...
(Date:5/26/2016)... ... 2016 , ... North Cypress Medical Center hosted its 9th Annual ... With the help of community partners, the event organizers raised $45,000 for the ... service members and their families through health, wellness, and therapeutic support. , A ...
(Date:5/26/2016)... FL (PRWEB) , ... May 26, 2016 , ... The ... of events featuring guest speaker Dr. Adonis Maiquez MD, ABAARM. Dr. Adonis , ... and Regenerative Medicine, and a member of the Institute for Functional Medicine. , He ...
Breaking Medicine News(10 mins):